Our findings that ICI immunotherapy relies on tumor cell-intrinsic RIPK3/MLKL signaling are in line with previous reports demonstrating that artificial activation of the necroptosis pathway can boost ICI antitumor efficacy. The gene discussed is MLKL; the disease is neoplasm.